Ozanimod

Introduction Overview

Generic Name

ozanimod

Brand Name

Zeposia

Dosage Form

oral capsule (0.23 mg, 0.46 mg, 0.92 mg)

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Ozanimod is administered orally and is well absorbed through the gastrointestinal tract. Peak plasma concentrations typically occur within a few hours after administration, indicating efficient absorption. Food does not significantly affect the bioavailability of ozanimod, allowing flexibility with regard to meal timing. Pharmacokinetic studies demonstrated that ozanimod has linear kinetics over the therapeutic dose range. The drug exhibits high permeability across the intestinal mucosa, facilitating rapid entry into systemic circulation. Clinical studies also indicate that the rate of absorption can be influenced by gastrointestinal motility and presence of concurrent medications that alter gastric pH, although these effects are generally minimal and not clinically significant.

Distribution:
Ozanimod has a large volume of distribution, reflecting extensive tissue penetration including immune-related organs. Protein binding of ozanimod is moderate to high, predominantly binding to albumin in plasma. The drug is lipophilic, enhancing its ability to cross cellular membranes and target sphingosine 1-phosphate (S1P) receptors on lymphocytes and other cells. Ozanimod and its active metabolites readily cross the blood-brain barrier, which is relevant for its efficacy in multiple sclerosis (MS) by modulating neuroinflammatory pathways. The distribution phase is rapid, with steady-state concentrations achieved within a few days of continuous dosing.

Metabolism:
Ozanimod undergoes extensive hepatic metabolism primarily via multiple enzymatic pathways including cytochrome P450 (CYP) enzymes, flavin-containing monooxygenase (FMO), and non-CYP mediated pathways. The parent compound is metabolized into several active metabolites that contribute to its pharmacologic effect. The principal metabolic transformations include oxidative metabolism followed by glucuronidation and other phase II conjugations. Metabolism is impacted by hepatic function, and drug interactions affecting metabolic enzymes may alter ozanimod plasma levels. Genetic polymorphisms in metabolic enzymes could influence metabolism rate but have not resulted in significant clinical variability thus far.

Elimination:
The elimination of ozanimod involves both renal and fecal routes, with most of the administered dose cleared as metabolites. The terminal elimination half-life ranges between 17 to 21 hours, supporting once-daily dosing. Clearance is primarily hepatic, although renal excretion of metabolites accounts for a modest proportion. The drug’s metabolites are pharmacologically active and have similar elimination profiles, contributing to overall drug exposure. Factors such as renal impairment or liver disease may affect elimination kinetics, requiring cautious use or monitoring in such populations. Clinical pharmacokinetic studies confirmed that ozanimod's elimination is consistent and predictable under normal physiological conditions.

Dosage Forms

Available Dosage Forms:
Ozanimod is available as oral capsules in multiple dosage strengths to allow for dose titration and individualized therapy. Specifically, the available capsule strengths include 0.23 mg, 0.46 mg, and 0.92 mg. These capsules are often packaged in a 7-day starter pack containing capsules of varying doses and colors designed to gradually increase the dose and mitigate initial side effects such as bradycardia.

Dosages for Adults and Adolescents:
The standard adult dosing regimen for both multiple sclerosis and moderately to severely active ulcerative colitis begins with a titration phase: Days 1-4 receive 0.23 mg orally once daily, days 5-7 receive 0.46 mg orally once daily, followed by maintenance dosing of 0.92 mg orally once daily starting on day 8. Dose escalation under physician supervision is crucial due to the drug's potential cardiac effects during initiation. Dosing guidelines currently do not include pediatric populations as safety and efficacy have not been established in children and adolescents.

Specific Patient Populations:
In patients with hepatic or renal impairment, dosing adjustments may be required based on clinical judgment, although no formal dose modification guidelines are available. The drug should be used with caution in patients with cardiac conditions and certain genotypes, necessitating pre-treatment screening. Treatment should not be started in patients who have used monoamine oxidase inhibitors (MAOIs) within the past 14 days. Pregnancy requires thorough risk-benefit assessment due to potential fetal harm. In immunocompromised patients, vigilant monitoring for infections is recommended given ozanimod's immunosuppressive properties.

Mechanism Of Action

Ozanimod is a selective modulator of sphingosine 1-phosphate (S1P) receptors, primarily targeting the S1P1 and S1P5 receptor subtypes. By binding to these G protein-coupled receptors, ozanimod acts as a functional antagonist, inducing receptor internalization and degradation. This modulation results in sequestration of lymphocytes within lymph nodes, thereby preventing their egress into the peripheral circulation and subsequent infiltration into the central nervous system (CNS) or inflamed tissues.

At the molecular level, ozanimod's binding to S1P1 receptor subunits on lymphocytes disrupts the normal signaling cascades that govern lymphocyte trafficking. The drug indirectly reduces immune-mediated inflammatory responses by decreasing the population of circulating autoreactive lymphocytes which contribute to demyelination in multiple sclerosis and inflammation in ulcerative colitis. Additionally, ozanimod also interacts with S1P5 receptors expressed on oligodendrocytes and CNS cells, which may support neuroprotective effects and remyelination.

Biochemical interactions include regulation of potassium channels in cardiac myocytes through S1P1 receptor influence, explaining initial transient bradycardia observed during drug initiation. Ozanimod's highly selective receptor profile differentiates it from less selective S1P modulators, minimizing off-target effects and potentially reducing adverse reactions.

Clinical studies have demonstrated that ozanimod reduces relapse rates, decreases MRI lesion activity, and slows brain atrophy in MS patients, confirming the clinical relevance of its immunomodulatory mechanism. In ulcerative colitis, it achieves clinical remission by limiting lymphocyte-mediated mucosal inflammation. Comparative studies show ozanimod offers advantages over earlier agents in its class, combining efficacy with a favorable safety profile and improved tolerability.

Pharmacological Actions

Selective modulation of sphingosine 1-phosphate (S1P) receptors, primarily S1P1 and S1P5 subtypes.
Prevention of lymphocyte egress from lymphoid tissues, reducing circulating autoreactive lymphocytes.
Immunosuppressive action that diminishes neuroinflammatory and mucosal inflammatory responses.
Neuroprotective effects via S1P5 receptor interaction on CNS oligodendrocytes promoting remyelination.
Transient cardiac slowing by modulating S1P1 receptors on cardiac pacemaker cells.
Reduction of relapse rates and MRI lesion formation in relapsing multiple sclerosis.
Induction of clinical remission in moderately to severely active ulcerative colitis by suppressing immune cell trafficking.
Minimal off-target receptor activity leading to improved safety and tolerability compared to non-selective S1P modulators.
Slowing of brain atrophy progression in multiple sclerosis patients supporting neuroprotection.
Immunomodulation without profound systemic immunosuppression, lowering risk of opportunistic infections compared to broad immunosuppressants.
Influence on potassium channel activity in cardiac tissue resulting in dose-dependent heart rate effects.

Therapeutic Or Clinical Uses

Treatment of relapsing forms of multiple sclerosis including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS in adults.
Management of moderately to severely active ulcerative colitis in adult patients.
Reduction of multiple sclerosis relapse rates and neurological disability progression.
Induction and maintenance of clinical remission and mucosal healing in ulcerative colitis.
Option for patients with specific genotypes suitable for ozanimod therapy after genetic testing.
Alternative oral immunomodulatory treatment to injectable or infusion therapies for multiple sclerosis.
Reducing brain atrophy in MS patients to preserve neurologic function over time.
Treatment avoiding some systemic effects of broader immunosuppressants or biologics by selective receptor targeting.
Use in patients with multiple sclerosis who are unsuitable for or intolerant to other disease-modifying therapies.
Management in ulcerative colitis patients with inadequate response to conventional therapies.
Potential neuroprotection and anti-inflammatory effects applicable to other immune-mediated CNS diseases under investigation.

Side Or Adverse Effects

Bradycardia and other heart rate abnormalities, especially during the initial dose titration period.
Upper respiratory tract infections and increased risk of serious infections due to immunosuppression.
Liver function test abnormalities including elevated transaminases and potential hepatotoxicity.
Headache and back pain as common neurological complaints during therapy.
Urinary tract infections and related symptoms such as dysuria and frequency.
Blood pressure alterations, including hypertension or hypotension episodes.
Cold symptoms such as nasopharyngitis, sneezing, and sore throat.
Visual disturbances including blurred vision, photophobia, and possible macular edema.
Potential allergic reactions manifesting as rash, urticaria, or angioedema.
Symptoms of infection including fever, cough, rash, and increased sensitivity to light.
Nausea, vomiting, upper abdominal discomfort, and anorexia indicating liver involvement.
Risk of rebound disease activity or worsening of MS symptoms upon abrupt discontinuation.
Dizziness or lightheadedness related to blood pressure changes or cardiac effects.
Rare but serious cardiac events including atrioventricular block in at-risk individuals.
Fatigue and malaise potentially impacting quality of life during treatment.

Precautions

Pre-treatment screening for heart conditions such as AV block, sick sinus syndrome, recent heart failure, myocardial infarction, arrhythmias, or stroke is mandatory.
Genotypic testing to confirm patient eligibility based on metabolic profile before initiating therapy.
Avoid initiation in patients who have used monoamine oxidase inhibitors (MAOIs) within the last 14 days.
Monitoring for infections is essential due to prolonged immunosuppressive effects lasting up to three months post-therapy.
Baseline and periodic liver function tests to detect hepatotoxicity early.
Avoid live vaccines one month prior to, during, and for at least three months after treatment due to diminished vaccine efficacy and risk of infection.
Caution in patients with a history of uveitis or macular edema; regular ophthalmologic assessments are advisable.
Use effective contraception during treatment and for at least three months following discontinuation due to teratogenic potential.
Gradual dose escalation per recommended titration schedules to mitigate cardiac adverse effects.
Avoid concomitant use with other drugs that can affect heart rhythm or slow AV conduction without close monitoring.
Inform patients about signs of infection, cardiac symptoms, and visual changes for prompt evaluation.
Close monitoring in patients with respiratory conditions including sleep apnea due to risk of exacerbation.
Consideration of vaccine status and immune competence prior to initiating therapy.
Discontinuation or dose adjustment considerations in hepatic or renal impairment, pending clinical evaluation.
Counseling patients about potential transient bradycardia and advising caution with activities requiring alertness.

Warnings

Risk of serious and sometimes fatal infections due to immunosuppression; infection risk may persist for up to three months after stopping ozanimod.
Contraindicated in patients with recent or ongoing serious cardiac conditions including recent heart failure, myocardial infarction, stroke, or uncontrolled arrhythmias.
Not to be used in patients with untreated severe sleep apnea due to risk of exacerbation.
Potential for transient bradycardia and heart block, necessitating cardiac monitoring during initiation.
Avoid use with monoamine oxidase inhibitors (MAOIs), with a mandatory 14-day washout period before starting ozanimod.
Potential fetal harm; contraindicated in pregnancy unless benefits outweigh risks, and requires effective contraception.
Live vaccines should be avoided during treatment and for several months after due to impaired immune response.
Abrupt discontinuation can lead to rebound MS disease activity; gradual discontinuation and medical supervision recommended.
Use caution in patients with pre-existing liver disease due to risk of hepatotoxicity.
Patients should be warned about symptoms of vision changes, indicating possible macular edema requiring urgent evaluation.
Potential for hypertension and hypotension warranting regular blood pressure monitoring.
Drug interactions with other immunosuppressants or cardiac medications can increase adverse event risk.
Delayed clearance with possible prolonged immunosuppressive effects requiring extended precautions after cessation.
Risk of worsening MS symptoms if treatment is stopped without medical guidance.
Potential neurological adverse events like seizures or confusion may occur and require prompt medical attention.

Contraindication

Known hypersensitivity to ozanimod or any component of the formulation.
Recent (within 6 months) history of heart failure, myocardial infarction, stroke, transient ischemic attack, or unstable angina.
Presence of second-degree or higher atrioventricular (AV) block or sick sinus syndrome unless a functioning pacemaker is present.
Severe untreated sleep apnea (obstructive or central).
Concomitant use or recent use (within 14 days) of monoamine oxidase inhibitors such as isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, or tranylcypromine.
Patients with severe hepatic impairment without close monitoring and adjustment.
Active serious infections or immunosuppressed states where further immunosuppression would be hazardous.
Pregnancy where benefits do not outweigh the potential risks to the fetus.
Patients unable to comply with required cardiac monitoring during drug initiation.
Known concomitant use of other drugs that cause significant bradycardia or AV conduction abnormalities without appropriate management.
History of macular edema unless benefits outweigh risks and monitoring is feasible.
Patients who have not been evaluated for varicella zoster immunity without prior vaccination.
Any contraindication to immunosuppressive therapy by clinical judgment.
Known hypersensitivity reactions to similar S1P modulators.
Patients with prolonged QT interval or concomitant use of other QT-prolonging agents if not carefully monitored.

Drug Interactions

Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated; a 14-day washout period is mandatory before ozanimod initiation.
Heart rhythm medications such as amiodarone, disopyramide, dofetilide, dronedarone, ibutilide, procainamide, quinidine, and sotalol may increase risk of cardiac adverse events when used with ozanimod.
Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs) and tricyclics, may have additive effects on heart conduction and CNS adverse effects.
Drugs that weaken the immune system such as cancer chemotherapeutics, systemic corticosteroids, and immunosuppressive agents may increase infection risk when combined with ozanimod.
Rifampin and gemfibrozil may affect ozanimod metabolism, potentially altering plasma concentrations and efficacy.
Antiplatelet agents like clopidogrel may increase bleeding risk; clinical monitoring is advised.
Parkinson’s disease medications may have interactions affecting CNS activity when used concomitantly.
Opioid analgesics combined with ozanimod may increase CNS depression risk and require cautious use.
Vaccines, especially live attenuated vaccines, may have reduced efficacy during and after ozanimod treatment.
Co-administration with inhibitors or inducers of cytochrome P450 enzymes can alter ozanimod plasma levels.
Herbal supplements such as St. John's Wort may induce metabolism leading to subtherapeutic levels.
Use with other drugs causing bradycardia or AV block increases risk of serious cardiac events.
Concomitant administration with medications that raise blood pressure or cause hypotension may require dose adjustments and frequent monitoring.
Interactions with proton pump inhibitors or antacids appear minimal but should still be reviewed clinically.
Multiple-drug regimens common in HIV, cancer, or organ transplant patients necessitate careful interaction assessment.

Preparations Of The Drug

Oral capsules available in 0.23 mg, 0.46 mg, and 0.92 mg strength formulations for flexible dosing and titration.
7-day starter pack with color-coded capsules to facilitate dose escalation and minimize cardiac adverse effects during initiation.
Capsules designed for oral administration with or without food.
Available as prescription-only medication requiring physician supervision and genotype testing before initiation.
Packaged with patient information leaflets detailing dosing schedules, side effect management, and safety precautions.
Storage recommendations include keeping at room temperature, protected from moisture and heat.
No available formulations for pediatric or parenteral use; strictly oral administration.
Manufactured to comply with pharmaceutical standards for purity, potency, and stability.
No generic formulations currently available; branded as Zeposia.
Supplied in blister packs for convenience and dose adherence monitoring.
Includes tamper-evident packaging to ensure product integrity.
Accompanied by comprehensive medication guides focused on immunosuppression risks and cardiac monitoring.
Chemical formulation as ozanimod hydrochloride salt to optimize solubility and bioavailability.
Compliance packaging options may be available to enhance patient adherence.
No topical, injectable, or inhaled versions; systemic immunomodulation is achieved via oral route.